

<insert name of clinician> <Address> Southampton, SO16 6YD <email>

<insert date>

<Insert GP name> <Insert GP address>

Dear Dr <insert GP name>

Reference patient: <insert patient name; NHS number and date of birth>

The above patient took part in the REFLEX testing for metabolic associated fatty liver disease (MAFLD) in patients with type 2 diabetes study on *<insert date>*.

<Insert patient name> agreed that we may inform you of their liver assessment finding:

FibroScan result:

<insert liver stiffness and steatosis readings, and IQR/MED>

Table 1: Interpretation of FibroScan results					
Liver stiffness reading interpretation ¹			CAP (controlled attenuation parameter) score interpretation ²		
Fibroscan reading	Fibrosis stage*	Interpretation	CAP score	Steatosis stage	Accumulated fat in the liver
<6.0 kPa	FO	No scarring	<250 dB/m ²	S0	<11%
≥6.0 kPa to 8.1 kPa	F1	Mild fibrosis	>250 dB/m ² and <301 dB/m ²	S1	11% and 33%
≥8.2 kPa to 9.6 kPa	F2	Moderate fibrosis	$>\!301dB/m^2$ and $<\!325dB/m^2$	S2	34% and 66%
≥9.7 kPa to 13.5 kPa	F3	Severe fibrosis	>325 dB/m ²	S3	>66%
≥13.6 kPa	F4	Advanced fibrosis or cirrhosis			

¹Liver biopsy validated fibrosis stages; ¹Eddowes PJ, Sasso M, Allison M, et al. Accuracy of FibroScan Controlled Attenuation Parameter and Liver Stiffness Measurement in Assessing Steatosis and Fibrosis in Patients With Nonalcoholic Fatty Liver Disease. Gastroenterology. 2019 May;156(6):1717-1730. doi: 10.1053/j.gastro.2019.01.042; ²PLoS One. 2014 Jun 5;9(6):e98689. doi: 10.1371/journal.pone.0098689. eCollection 2014.

 Diagnosis:
 <insert diagnosis and interpretation>

 Action:
 Please <insert any relevant clinical notes as advised by study clinicians at the time of assessment>

At the time of the VCTE assessment *<insert patient name>* was advised of *<his/her/their>* VCTE result.

Patient follow up has now finished.

If you have any queries, please contact the study team on: <insert telephone number and email address>

With kind regards

<Insert clinician name and position>

Cc: <insert patient name>

26 March 2023 B1_PatientLetter_V2 IRAS project ID: 326212 ERGO ID: 80205